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Abstract: The recent Kidney Disease Outcomes Quality Initiative (K-DOQI) guidelines suggest an
early start of protein restriction, raising issues on willingness to change dietary habits. The aim of
this exploratory real-life study was to report on a test of dietary products (protein-free, not previously
available in France) in a large, mainly elderly, chronic kidney disease (CKD) population (220 patients,
median age: 77.5 years, Charlson comorbidity index (CCI): seven, malnutrition inflammation score
(MIS): five, estimated glomerular filtration rate (eGFR): 26 mL/min, also as a means to tailor further
implementation strategies. Forty-nine patients (22.28%) were considered to be poor candidates
for the trial (metabolically unstable or with psychological, psychiatric or logistic barriers); of the
remaining 171, 80.70% agreed to participate. Patients to whom the diet was not proposed had lower
eGFR and higher comorbidity (eGFR 21 vs. 27 p = 0.021; MIS six vs. four p: <0.001). Patients who
refused were 10 years older than those who accepted (83 vs. 73 years p < 0.001), with a higher CCI
(eight vs. seven p = 0.008) and MIS (five vs. four p = 0.01). In the logistic regression, only age was
significantly associated with refusal to participate (Odds ratio (OR): 5.408; 95% CI: 1.894 to 15.447).
No difference was found according to low/intermediate/high frequency of weekly use of protein-free
food. Our study suggests that most of the patients are ready to test new diet approaches. Only old
age correlated with refusal, but frequency of implementation depended on individual preferences,
underlying the importance of tailored approaches to improve adherence.
Keywords: chronic kidney disease; protein restriction; protein-free food; nutrition in CKD;
low-protein diet
1. Introduction
Chronic kidney disease (CKD) is a complex heterogeneous disease in terms of pathogenesis,
clinical manifestations, speed of progression, and development of complications. However, despite its
heterogeneity, when over 50–70% of the renal parenchyma is damaged, a progressive loss of kidney
function is usually observed regardless of the initial cause. Slowing the progression of renal damage
becomes crucial in earlier phases, while metabolic stabilization in late CKD phases sometimes makes
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it possible to postpone dialysis. For this purpose, nutritional management, in particular protein
restriction, plays a role in protecting kidney function [1–16]. In fact, the new guidelines of the Kidney
Disease Outcomes Quality Initiative (K-DOQI) suggest protein restriction should be introduced early,
when possible in stage three, with a profile adapted to each patient, provided that the patients are
metabolically stable and free from acute diseases—especially if these diseases potentially induce
wasting [17].
The understanding of the link between uremic syndrome and exogenous protein catabolism can
be traced back to the nineteenth century; however, only in the Sixties, mainly thanks to Giordano,
Giovannetti and Maggiore, low-protein diets were systematically prescribed for patients with advanced
renal insufficiency [18–20]. While several dietary approaches were and are still available, Maggiore is
mainly behind the definition of low-protein diets based upon the substitution of usual bread and
pasta with protein-free equivalents. These products are commonly used in Italy where they are fully
reimbursed and are a cornerstone of dietary CKD management [18,21–23].
The dietary management of CKD encountered different fortunes over the subsequent decades
but it is now increasingly recognized as fundamental for delaying the need for renal replacement
therapy [7,10–12,24–26]. The latest K-DOQI guidelines on nutrition in patients with CKD strongly
recommend (evidence level: 1A) protein restriction not only to reduce the risk of end-stage renal
disease but also death [17]. When patients following such diets are carefully assessed, the risk of
malnutrition is now far lower than in the past [2,24,27–30].
However, following a low-protein diet is difficult and elderly patients, who represent the vast
majority of our population, are often considered to be “resistant” to change [21].
In this context, we decided to carry out this study to explore patients’ willingness to change their
diet when offered new options. Enrolling patients in a test of protein-free food that had not previously
been available in France allowed us to evaluate attitudes towards dietary changes in a large cohort of
high-comorbidity elderly patients with advanced CKD.
2. Materials and Methods
2.1. Study Setting
The study was conducted in the advanced chronic kidney failure unit (UIRAV Unite pour
l’Insuffisance Rénale AVancée) that opened in November 2017 in the Centre Hospitalier Le Mans
(CHM) in France. CHM is one of the largest non-university hospitals in France with a referral area of
about 500,000 inhabitants. UIRAV provides care for outpatients with advanced kidney disease or with
specific clinical needs (including pregnancy). Three nutritionists and two nephrologists work in the
unit, providing integrated follow-up including dietary advice and nutritional evaluation [31].
2.2. Study Population
The study population encompassed all the 220 stage 3 to stage 5 patients seen by UIRAV between
24 March 2019 and 24 June 2020. In keeping with the KDOQI guidelines, a tailored protein reduction
policy was recommended for patients in stages 3–5 without contraindications (including malnutrition,
or being metabolically unstable, the latter encompassing the main conditions associated with short life
expectancy) [17].
Malnutrition was clinically defined, corresponding overall to subjective global assessment (SGA)
score C or to switch between SGA scores A and B, while diets were prescribed in stable patients rated
as SGA B. Short life expectancy was likewise considered empirically as a life expectancy of less than
3 months.
Patients were offered protein-free products in the context of the Pro-Re-Pro (Protein restriction for
retarding CKD Progression) study, prospectively testing the feasibility, implementation, and results of a
tailored approach to low-protein diets in CKD stages 3–5. No age limit was posed, but the unit gathers
patients with advanced CKD, particularly if at high morbidity, notably cardiovascular. This explains
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why the median age is so high, in a setting where the median age at the start of dialysis is above
70 years.
The reasons why some patients were not asked to participate in the test and patients’ reasons
for deciding not to try the new products were recorded, while for patients who agreed to participate,
compliance, barriers and satisfaction were recorded.
All recruited patients had performed at least one previous nephrology visit in the unit, or in the
other units ran by the same team, and 90% of them had visited more than once, in keeping with the
policy of progressively prescribing dietary changes, according to a personalized approach. The median
interval between the first enrollment in the UIRAV and the proposal of the test was 244 days.
The variables analyzed include gender, ethnicity, age, body mass index (BMI), dietary prescriptions
at the time of the test, serum creatinine, estimated glomerular filtrate rate (calculated by
means of the Chronic Kidney Disease Epidemiology Collaboration equation—CKD-EPI) [32],
CKD stage, proteinuria, Charlson comorbidity index (CCI), subjective global assessment (SGA)
index, malnutrition inflammation score (MIS), and, for patients who agreed to participate in the study,
the Word Health Organisation Quality of Life Sort questionnaire (WHOQOL-BREF) was completed at
baseline and a custom-made satisfaction questionnaire was completed after testing [33–35].
Chronic kidney disease was defined as is customary, according to the K-DOQI guidelines,
based on the presence of either decreased kidney function (estimated glomerular filtration rate
(eGFR) < 60 mL/min) or other morphological or urinary alterations lasting for at least 3 months. All the
patients enrolled in the study had been classified as having CKD with at least one confirmatory eGFR.
2.3. Design of the Study and Choice of the Products
During their routine nephrology visit, either the caregiver nephrologist or a resident of the unit
asked patients if they were interested in testing protein-free products, including at least one of four
types of bread (sandwich bread, baguette, country loaf, crisp bread), two types of pasta (anellini and
penne) and two types of cookies (fruit bars and wafers). The clinical team is small and consists of
two nephrologists and one resident, working in close partnership, and thus ensuring homogeneous
information and recruitment policy.
They were given portions of the bread, pasta, and cookies for 4 meals. One portion was calculated
as 80 g of pasta and 50 g of bread, 2–4 biscuits and one snack, respectively. All products were given free
of charge and no biochemical test was added to the usual routine; all biochemical tests are reimbursed
for patients with advanced CKD in the French system.
After testing the products, at their next visit or during a telephone interview (1–3 months after the
test), patients were asked to complete the satisfaction questionnaire.
2.4. Satisfaction Questionnaire
The questionnaire consisted of 3 parts:
- Assessment of satisfaction with the products tested, based on a 1–10 visual analogue scale;
- Identification of the frequency with which new products could replace products they normally ate;
- Semi-structured questions on possible barriers (price, variety of products, therapeutic efficacy,
ease of supply, reimbursement, taste) to their use.
Readiness to change was scored as: “low” (max two portions/week), “moderate” (one portion/day),
and “high” (at more than one portion/day).
2.5. Statistical Analysis
Statistical analysis was performed with SPSS v.14 (IBM corp., Armonk, NY, USA) and JASP v.0.11.1
(JASP Team, Amsterdam, The Netherlands). Descriptive analysis was conducted as appropriate;
the Shapiro–Wilk test was used to verify the normality distribution of the data, and the Levene’s test
was used to verify homoscedasticity. According to the distribution of the data, the unpaired t-test
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was used to compare two groups (e.g., proposed vs. not proposed) or the ANOVA Test was used to
compare n-groups (e.g., low, moderate and high willingness to change), otherwise the Mann–Whitney
test was applied to compare two groups or the Kruskal–Wallis test was used for additional comparisons.
Category results were presented as size with their percentage and compared with the chi-squared test
or Fisher’s exact test for small subgroups.
Logistic regressions were performed to test the following two outcomes: refusal to try products and
low willingness to change. The following explanatory variables were used: age (dichotomized ≥80 years),
CCI (dichotomized ≥7), SGA score (B-C vs. A) and gender (females vs. males). The MIS score was not
employed because of collinearity with Charlson and SGA scores. The variables were chosen either
because they were clinically relevant (gender, SGA, Charlson) or because they were significant in the
descriptive analysis (age).
A two-tailed alpha risk at 5% was considered statistically significant.
2.6. Ethical Issues
The study was conducted in accordance with the Declaration of Helsinki.
The study was a part of the Pro-Re Re-Pro study. This is a prospective, monocentric, non-randomized
study on the implementation of nutritional approaches to delay dialysis. The study started on 1 April 2019
and will end on 1 April 2023. The protocol of the Pro-Re Re-Pro study was approved by the ethics
committee of the University Hospital de Toulouse (Comité de Protection des Personnes (CPP)) on
7 December 2018. Informed consent was obtained from each patient and there was anonymous
management of clinical data.
3. Results
3.1. Baseline Data
Figure 1 presents the study flow chart. Participation in the study was not proposed to 49 patients
for reasons that included cognitive impairment (13/49), imminent dialysis (8/49) and short life
expectancy—metabolic instability (10/49), other reasons (18/49) included follow-up based in another
setting and language barriers. Participation in the study was proposed to 171 patients (77.73%).
Of these, 33 (19.30%) refused and 138 (80.70%) agreed to participate. One hundred thirty-one (96.32%)
satisfaction questionnaires were returned and only seven were not (two because the patients had died
and five for various causes); one questionnaire returned was too incomplete to be analyzed.
Table 1 reports the characteristics of the population divided as shown in the flow chart into four
subsets (proposed vs. not proposed; agreed vs. refused). Kidney function improved in two patients
who reached an eGFR of 61 and 68 mL/min, respectively, shifting from CKD stage 3a to stage two at
recruitment, and thus explaining the eGFR range reported in Table 1.
Patients to whom the trial was not proposed had lower eGFR and higher comorbidity, in keeping
with the shared indication not to consider metabolically unstable patients for protein restriction
policies [17]; furthermore, about two-thirds of these patients were on an unrestricted diet (no restriction,
or normalization of protein intake at 0.8 g/kg/day).
Conversely, patients who refused to try the new products were about 10 years older than those
who accepted and, consequently, they displayed significantly higher CCI and MIS scores, and a lower
prevalence of cases without signs of malnutrition.
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Figure 1. Study flow chart. CKD: chronic kidney disease; UIRAV: Unit for the follow-up of 
advanced CKD; CCI: Charlson Comorbidity Index; MIS: Malnutrition Inflammation Score; SGA: 
Subjective Global Assessment. 
Table 1. Baseline characteristics of the population. 
 Proposed Not Proposed p Accepted Refused p 
n 171 49  138 33  
Gender, n (%)   
0.006 
  
0.861 males, n (%) 117 (68.42%) 23 (46.94%) 94 (68.12%) 23 (69.70%) 
females, n (%) 54 (31.58%) 26 (53.06%) 44 (31.88%) 10 (30.30%) 
Age, median (min–max) 77 (25–103) 79 (27–95) 0.156 73 (25–97) 83 (55–103) <0.001 











Caucasian, n (%) 165 (96.49%) 47 (95.92%) 0.850 132 (95.65%) 33 (100%) 0.223 
Charlson Comorbidity Index, 
median (min–max) 
7 (2–17) 8 (2–14) 0.299 7 (2–17) 8 (3–13) 0.008 




SGA A 154 (90.06%) 31 (63.27%) 128 (92.75%) 26 (78.79%) 
SGA B 17 (9.94%) 17 (34.69%) 10 (7.25%) 7 (21.21%) 
SGA C 0 1 (2.04%) 0 0 
MIS score, median (min–max) 4 (0–12) 6 (1–13) <0.001 4 (0–12) 5 (1–12) 0.010 
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Figure 1. Study flow chart. CKD: chronic kidney disease; UIRAV: Unit for the follow-up of advanced
CKD; CCI: Charlson Comorbidity Index; MIS: Malnutrition Inflammation Score; SGA: Subjective
Global Assessment.
Table 1. Baseline characteristics of the population.
Proposed Not Proposed p Accepted Refused p
n 171 49 138 33
Gender, n (%)
0. 06 0.861males, n (%) 117 (68.42%) 23 (46.94%) 94 (68.12%) 23 (69.70%)
females, n (%) 54 (31.58%) 26 (53.06%) 44 (31.88%) 10 (30.30%)
Age, median
(min–max) 77 (25–103) 79 (27–95) 0.156 73 (25–97) 83 (55–103) <0.001
BMI (kg/ 2),
median (min–max)
28.25(17.43–51.20) 28.67(19.81–38.38) 0.978 28.73(18.56–51.20)
26.56
(17.43–44.29) 0.051
Caucasian, n (%) 165 (96.49%) 47 (95.92%) 0.850 132(95.65%) 33 (100%) 0.223
Charlson
Comorbidity In ex,
median ( i – ax)
7 (2–17) 8 (2–14) 0.299 7 (2–17) 8 (3–13) 0.008
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Table 1. Cont.
Proposed Not Proposed p Accepted Refused p
SGA score, n (%)
<0.001 0.016
SGA A 154 (90.06%) 31 (63.27%) 128(92.75%) 26 (78.79%)
SGA B 17 (9.94%) 17 (34.69%) 10 (7.25%) 7 (21.21%)
SGA C 0 1 (2.04%) 0 0
MIS score, median
(min–max) 4 (0–12) 6 (1–13) <0.001 4 (0–12) 5 (1–12) 0.010
sCreatinine (mg/dL),











eGFR stage, n (%)
<0.001 0.026
Stage 3a * 14 (8.19%) 4 (8.16%) 7 (5.07%) 7 (21.21%)
Stage 3b 59 (34.50%) 15 (30.61%) 49 (35.51%) 10 (30.30%)
Stage 4 79 (46.20%) 13 (26.53%) 66 (47.83%) 13 (39.39%)
Stage 5 19 (11.11%) 17 (34.69%) 16 (11.59%) 3 (9.09%)
Proteinuria (g/day),





Diabetes, n (%) 73 (42.69%) 18 (36.73%) 0.455 60 (43.48%) 13 (39.39%) 0.670
Protein intake, n (%)
<0.001 0.200
Unrestricted, n (%) 0 12 (24.49%) 0 0
0.8 g/kg/day, n (%) 102 (59.65%) 21 (42.86%) 78 (56.52%) 24 (72.73%)
0.6 g/kg/day, n (%) 45 (26.32%) 9 (18.37%) 40 (28.99%) 5 (15.15%)
0.6 g/kg/day
supplemented, n (%) 24 (14.03%) 7 (14.29%) 20 (14.49%) 4 (12.12%)
Note: statistically significant data in bold. Abbreviations: BMI: body mass index; SGA: subjective global assessment;
MIS: malnutrition inflammation score; eGFR: estimated glomerular filtration rate; eGFR-EPI: estimated glomerular
filtration rate according to the Chronic Kidney Disease Epidemiology Collaboration equation. * Stage 3a includes 2
patients in stage 2 that were previously in stage 3a and that subsequently had an improvement in their renal function.
3.2. Willingness to Change and Satisfaction with the Test
Table 2 reports the characteristics of the patients with respect to their willingness to change their
diets, scored according to the frequency of integration of the suggested products in their weekly
meal plans. As shown in Table 2, no significant difference was found in the three groups with the
parameters analyzed.
The product patients liked best were the fruit bars, with a median score of nine on a 1–10 visual
analogue scale; pasta ranked second with a median of eight, while the bread products were not given
high scores (Figure 2).
Of the barriers analyzed (price, variety of products, therapeutic efficacy, ease of supply,
reimbursement, taste), the most important was taste, followed by logistic barriers (price, reimbursement)
and therapeutic efficacy. Ease of supply and variety were perceived as less relevant.
Nutrients 2020, 12, 3519 7 of 14








N 130 33 (25.38%) 49 (37.69%) 48 (36.92%)
Gender, n (%)
0.987males 22 (66.67%) 32 (65.31%) 32 (66.67%)
females 11 (33.33%) 17 (34.69%) 16 (33.33%)
Age, median (min–max) 77 (25–97) 72 (35–96) 74 (37–97) 0.897
BMI (kg/m2),
median (min–max)
28.25 (20.31–51.20) 28.04 (18.56–51.17) 29.02 (19.33–44.20) 0.951
Caucasian, n (%) 32 (96.97%) 47 (95.92%) 45 (93.75%) 0.774
Charlson score,
median (min–max) 7 (2–13) 7 (2–14) 7 (2–13) 0.746
SGA score, n (%)
0.999SGA A 31 (93.94%) 46 (93.88%) 45 (93.75%)
SGA B 2 (6.06%) 3 (6.12%) 3 (6.25%)
MIS score,
median (min–max) 4 (1–8) 4 (0–10) 3.5 (1–9) 0.129
sCreatinine (mg/dL),
median (min–max) 2.13 (1.15–5.77) 2.40 (1.31–5.40) 2.13 (0.90–9.14) 0.824
eGFR-EPI (mL/min),
median (min–max) 25 (7–58) 24 (10–55) 28 (6–60) 0.648
eGFR stages, n (%)
0.656
Stage 3a * 1 (3.03%) 4 (8.16%) 2 (4.17%)
Stage 3b 14 (42.42%) 12 (24.49%) 18 (37.50%)
Stage 4 15 (45.45%) 26 (53.06%) 23 (47.92%)
Stage 5 3 (9.09%) 7 (14.29%) 5 (10.41%)
Proteinuria (g/day),
median (min–max) 0.20 (0–6.50) 0.80 (0.10–7.70) 0.35 (0–8.10) 0.111
Diabetes, n (%) 16 (48.48%) 22 (44.90%) 18 (37.50%) 0.586
Protein intake, n (%)
0.199
Unrestricted, n (%) 0 0 0
0.8 g/kg/d, n (%) 24 (72.73%) 23 (46.94%) 27 (56.25%)
0.6 g/kg/d, n (%) 7 (21.21%) 16 (32.65%) 14 (29.17%)
0.6 g/kg/d, Ketosteril, n (%) 2 (6.06%) 10 (20.41%) 7 (14.58%)
WHOQOL-BREF domains,
median (min–max)
Domain 1: physical health,
median (min–max) 3.33 (2.17–4.00) 3.33 (2–4.33) 3.42 (2.14–4.71) 0.882
Domain 2: psychological,
median (min–max) 3.67 (2.33–4.5) 4 (2–5) 4 (2.17–5) 0.557











3.67 (2.67–4.50) 4 (2–5) 4 (1.67–5) 0.619
Domain 4: environment,
median (min–max) 3.63 (2.88–4.75) 3.63 (2.75–4.63) 3.82 (2.25–4.75) 0.790
Abbreviations: BMI: body mass index; SGA: subjective global assessment; MIS: malnutrition inflammation score;
eGFR: estimated glomerular filtration rate; eGFR-EPI: estimated glomerular filtration rate according to the Chronic
Kidney Disease Epidemiology Collaboration equation WHOQOL-BREF: World health organization quality of life
questionnaire, short form. * Stage 3a includes 1 patient now in stage 2, previously in stage 3a. One questionnaire
was too incomplete to be analyzed.Nutrie ts 2020, 11, x FOR PEER REVIEW 8 of 14 
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Age was the only covariate associated with patients’ willingness to test new products. Patients 
aged ≥80 years had an odds-ratio of 5.891 (unadjusted) and 5.408 (adjusted) in refusing to test new 
food products compared to younger patients (Table 3).  
Conversely, none of the variables tested were associated with the frequency with which 
patients indicated they would be willing to integrate the new food into their diet (Table 4). 
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3.3. Logistic Regression Analysis: Refusal to Participate in the Test and Low Willingness to Change
Age was the only covariate associated with patients’ willingness to test new products. Patients aged
≥80 years had an odds-ratio of 5.891 (unadjusted) and 5.408 (adjusted) in refusing to test new food
products compared to younger patients (Table 3).
Table 3. Logistic regression analysis: outcome: refuse of a diet trial.
95% Confidence Intervals
Odds-Ratio Lower Higher p-Value
Step 1 Gender (females/males) 0.643 0.257 1.608 0.345
Age (≥80 years) 5.408 1.894 15.447 0.002
Charlson (≥7) 1.039 0.300 3.600 0.952
SGA (B vs. A) 1.856 0.580 5.938 0.297
Step 2 Gender (females/males) 0.643 0.257 1.607 0.345
Age (≥80 years) 5.503 2.263 13.384 <0.001
SGA (B vs. A) 1.856 0.580 5.935 0.297
Step 3 Age (≥80 years) 5.308 2.197 12.826 <0.001
SGA (B vs. A) 1.639 0.532 5.051 0.390
Step 4 Age (≥80 years) 5.891 2.527 13.737 <0.001
Note: statistically significant data in bold.
Conversely, none of the variables tested were associated with the frequency with which patients
indicated they would be willing to integrate the new food into their diet (Table 4).
Table 4. Logistic regression analysis for low willingness to change.
95% Confidence Intervals
Odds Ratio Lower Higher p-Value
Step 1 Gender (females/males) 0.996 0.419 2.367 0.992
Age (≥80 years) 0.814 0.296 2.239 0.690
SGA (B vs. A) 1.043 0.177 6.135 0.963
Charlson (≥7) 1.292 0.506 3.298 0.593
Step 2 Age (≥80 years) 0.814 0.298 2.223 0.687
SGA (B vs. A) 1.041 0.183 5.935 0.964
Charlson (≥7) 1.292 0.508 3.289 0.591
Step 3 Age (≥80 years) 0.819 0.313 2.140 0.684
Charlson (≥7) 1.291 0.507 3.285 0.592
Step 4 Charlson (≥7) 1.180 0.513 2.714 0.696
Abbreviations: SGA: subjective global assessment.
4. Discussion
The newly released guidelines on dietary management of CKD underline the importance of
lowering protein intake in virtually all patients with advanced CKD [17]. In this context, attention has
shifted to how to accomplish this goal and what strategies should be implemented. Previous Italian
experiences have highlighted the role of protein-free food and the importance of offering patients a
choice of diets [5,8,11,18,23,36,37]. Protein-free food is an important support for protein restriction
in Italy, where these products are totally or partially reimbursed. However, these products are not
available in most other European countries and it is felt that cultural or compliance barriers may limit
interest in using them [22,38]. In this regard, we felt that testing patients’ attitudes would provide
insights into the potential candidates for dietary management and their overall willingness to change
dietary habits for health-related reasons.
The key point of our exploratory, real-life study was the assessment of the readiness to change
of a population affected by advanced CKD, who was asked to participate in a trial of protein-free
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food, which had not previously been tested. The population is characterized by a high median age,
both reflecting the local CKD population, whose median age at start of dialysis is above 70 years
overall, and the setting of care, since the unit gathers patients with advanced CKD, particularly if at
high morbidity, notably cardiovascular, or in the context of “conservative” pre-dialysis care.
The interest in this study is both general and specific. In a general sense, our study highlights
patients’ interest in changing their habits for a health goal and their ability to make the change. In a
specific sense, our study helps to identify strategies for introducing protein-free food in the diets of a
cohort of patients with different dietary habits. In this respect, the stepwise comparisons discussed
here support the decisional pathway.
Not all patients are good candidates for a diet trial. In our cohort, about one-fourth of our patients
(22.28%) were not considered for participation, due to short life expectancy (10/49), imminent dialysis
start (8/49), cognitive impairment (13/49) or other barriers (18/49). This information may be relevant in
clinical practice, as the new KDOQI guidelines clearly underline that the patients considered for a
protein restriction approach should be metabolically stable, a condition that does not encompass short
life expectancy and imminent dialysis start [17]. Additionally, our study may suggest that cognitive
impairment and logistic barriers may also be relevant in this regard.
However, the vast majority of our patients (77.73%) were considered potential candidates and in
fact 80.70% of them agreed to participate in the study. In the context of a largely elderly, high-comorbidity
population, patients who did not wish to test the new products were 10 years older (83 (55–103) years
of age vs. 73 (25–97), p < 0.001), and consequently had higher CCI and MIS scores (CCI: eight (3–13)
vs. seven (2–17); MIS four (0–12) vs. five (1–12)) than those who decided to participate, showing that
baseline characteristics, specifically age, often modulate attitudes towards dietary choices.
The test was generally well rated by those who participated. The vast majority of patients were
ready to change their previous eating habits by integrating low-protein products into their diets,
and only about a quarter (25.38%) of the patients were reluctant to change, indicating on the satisfaction
questionnaire that they would be willing to add the products in the test to their diet 0–3 times per week.
In keeping with the importance of individual food preferences, no difference was detected between
patients according to the frequency that they were ready to use the products they had tested.
An element of reflection is that pasta, the hallmark of the Italian cuisine, was one of the best-liked
foods, a sign of patients’ willingness not only to accept a “healthy product”, but also their openness to
different traditions. Food is a part of group identity and membership; however, with globalization,
people are learning to appreciate new foods [39,40]. In fact, Italian pasta was one of the foods French
patients, despite their strong cultural identity, liked best (Figure 2).
This study, which is one of the first to explore attitudes to integrating new products in the daily
diet of a large, elderly, high-comorbidity CKD cohort, has several limitations. It is a monocentric study
and the center’s particular system of CKD care may have played a role in influencing patients’ choices.
Moreover, it evaluates a test of short duration and has no follow-up; therefore, making it impossible to
assess efficacy, compliance and “diet tiredness”.
The roles of the patient–physician and patient–dietitian relationships were not explored. This is
probably an important point in motivating the patients towards testing a new approach, and eventually
following it in the long term. Indeed, in our center, a previous study aimed at assessing compliance in
a first cohort of patients highlighted that over 75% of the patients were able to attain the prescribed
dietary goals, suggesting that a flexible system of care was well adapted to our population [31].
Within these limits, our study shows that the “poor candidates” were a minority and may help
identify a potential implementation strategy for “good candidates” (Figure 3). The overall readiness to
change, which decreased as patients’ age increased, was found to be based on individual elements that
cannot be determined in advance, as is witnessed by the wide and overlapping range of ages in both
the cases of those who agreed to participate and those who did not.
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We suggest, therefore, that dietary options should be offered without preconceptions to all patients
that could potentially benefit from them. In patients ready to test changes to their diets, the factor that
made the difference regarding whether or ot they would be willing to add the proposed protein-free
food to their meals was taste. The lack of difference in baseline characteristics is in li e with personal
preference, and in keeping with the identification of taste as the main barrier to changing dietary habits.
Therefore, our data strongly support that patients should be offered a test phase during which changes
can be tailored to reflect their preferences. In our study, the products were given free of charge, all tests
were reimbursed, as per the usual French policy, and indeed no biochemical test was ad e to the usual
clinical management. However, logistic elements, most importantly reimbursement, were identified as
important barriers to the integration of protein-free food in the long-term. This should be kept in mind
when identifying implementation strategies, particularly when dealing with an elderly population,
such as ours, in which economic hurdles are often relevant.
Our exploratory study was not designed for answering questions regarding adherence, or for
assessing how much these products may help in reaching the targets recently reviewed and summarized
in the KDOQUI guidelines [17]. This is a very important point for future studies; indeed, according to
the Italian experience, there is no frequent “compensation” with protein rich food, since these products
are rich in calories and, on the contrary, allow eating food of animal origin more freely. The main
drawback in the Italian experience was low adherence, due to low palatability, which is one of the
reasons why we designed this study [8,41].
Our study, the first one aiming to assess the potential for integrating protein-free food, so far
essentially only used in Italy, in an elderly French population, may pave the way for multicentric
studies aimed at defining the role and the room for these or other similar products to improve dietary
adherence and reach the prescribed targets in different settings. Such a study could also highlight the
roles of different cultural backgrounds and of the center organization in promoting adherence to the
dietary prescriptions.
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5. Conclusions
Our study suggests that CKD patients are keen to alter their diet to improve health related
outcomes, and that even elderly and high-comorbidity patients are willing to change their dietary
habits, although very old age (≥80 years) is associated with lower willingness to test new food.
In patients who agreed to try the new products (protein-free food), the level of willingness to
integrate them in their daily meals reflected individual preferences and taste, and thus underlined the
importance of tailored approaches in improving adherence to protein-restricted diets in CKD patients.
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